That is true that VHI's share price reacts favourably after the press release of the deal. VHI is acquiring MedCurrent - a clinical decision support solution company that helps physicians make better decisions in real-time and optimize diagnostic orders, the deal would help VHI deploy $34M in total consideration. VHI did have a share issuance earlier this year for a total of $40.2M. This transaction would take the majority of that to proceed. VHI is a serial acquirer and investors tend to react favourably when a large deal is complete. There is not a lot of info here, but we have no reason to see it as a bad deal. It expands the breadth of the company, adds clients and executives, and looks good based on the information available. We remain bullish on VHI's prospect of being a serial acquirer.
5i Research Answer: